

June 13, 2023

BSE Limited Code: 532321

P J Towers, Dalal Street, <u>Mumbai-400001</u>

National Stock Exchange of India Limited

Exchange Plaza, C/1, Block G, Bandra-Kurla Complex, Bandra (East), Mumbai-400051

Re.: Press Release

Dear Sir / Madam,

Please find enclosed a copy of press release dated June 13, 2023 titled "Zydus receives final approval from the USFDA for Varenicline Tablets".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully, For, **ZYDUS LIFESCIENCES LIMITED**

DHAVAL N. SONI COMPANY SECRETARY

Encl.: As above



Code: Zyduslife



Zydus receives final approval from the USFDA for Varenicline Tablets

Ahmedabad, India, 13 June, 2023

Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as "Zydus") has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Varenicline Tablets, 0.5 mg and 1 mg (USRLD: Chantix® Tablets). The product will be launched shortly.

Varenicline tablets is indicated to treat smoking addiction. The drug will be manufactured at the group's formulation manufacturing facility at Ahmedabad SEZ, India.

Varenicline Tablets, 0.5 mg and 1 mg had annual sales of USD 501 mn in the United States (IQVIA MAT Mar. 2023).

The group now has 374 approvals and has so far filed over 442* ANDAs since the commencement of the filing process in FY 2003-04.

(*as of 31st March 2023)



For further information please contact: The Corporate Communications Department

Zydus Lifesciences Limited

CIN: L24230GJ1995PLC025878

(formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000 | website : www.zyduslife.com